US Medicare limits coverage of warfarin genetic testing to clinical trials
This article was originally published in Scrip
Executive Summary
The US Medicare programme has reaffirmed its initial decision against routine coverage of pharmacogenomic testing to predict patients' response to warfarin (Bristol-Myers Squibb's Coumadin and generics).